TC
EBS icon

Travelers Companies’s Emergent Biosolutions EBS Stock Holding History

Travelers Companies’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,486
Closed -$28K – 39
2013
Q3 		$28K Buy
+1,486
New +$26.5K 0.01% 34

Other funds holding EBS

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Travelers Companies's EBS Position: Q4 2013 in Review

Travelers Companies sold out of Emergent Biosolutions (EBS) in Q4 2013, closing a stake of 1,486 shares — an estimated $28K sold.

Travelers Companies first reported a position in EBS in Q3 2013 and held it in 1 quarter. The position peaked at $28K in Q3 2013. 133 funds tracked by Wall St. Rank hold EBS as of Q4 2013.

  • Travelers Companies reported no remaining Emergent Biosolutions position as of Q4 2013 after selling out during the quarter.
  • Travelers Companies sold 1,486 Emergent Biosolutions shares in Q4 2013, an estimated $28K.
  • Travelers Companies first reported a position in Emergent Biosolutions in Q3 2013 and held it in 1 quarter.
  • Travelers Companies's Emergent Biosolutions position peaked at $28K in Q3 2013.
  • 133 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2013.

Based on Travelers Companies's 13F filing for Q4 2013, filed 13 Feb 2014.